Expanded Access to ABT-414

Study Identifier
C16-478
CT.gov Identifier
NCT03123952
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Cancer - Other
    • Study Drug
  • ABT-414
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Inclusion Criteria: * Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation. * Health Care Provider (HCP) must have prior clinical trial experience with ABT-414. * The participant must not be eligible for an ABT-414 clinical trial. * Pediatric participants may be evaluated on a case by case basis.

    Protocol Summary

    This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

    Study Locations

    No locations found.